Literature DB >> 9067749

Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease.

C Eng1, L M Mulligan.   

Abstract

The RET proto-oncogene codes for a receptor tyrosine kinase thought to play a role in the development of neural crest and its derivatives. Mutations in the RET proto-oncogene have been found in patients with the multiple endocrine neoplasia type 2 syndromes (MEN 2), the related sporadic tumours medullary thyroid carcinoma and pheochromocytoma, and familial and sporadic Hirschsprung disease, a syndrome of congenital absence of enteric innervation. Germline mutations in one of eight codons within RET cause the three subtypes of MEN 2, namely, MEN 2A, MEN 2B, and familial medullary thyroid carcinoma. Somatic mutation in an overlapping group of nine codons have been found in a proportion of sporadic medullary thyroid carcinoma and pheochromocytoma. In contrast to MEN 2, approximately 25% of patients with Hirschsprung disease have germline mutations scattered throughout the length of RET.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9067749     DOI: 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.0.CO;2-M

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  40 in total

1.  Association of RET protooncogene codon 45 polymorphism with Hirschsprung disease.

Authors:  G Fitze; M Schreiber; E Kuhlisch; H K Schackert; D Roesner
Journal:  Am J Hum Genet       Date:  1999-11       Impact factor: 11.025

2.  Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression.

Authors:  S Borrego; M E Sáez; A Ruiz; O Gimm; M López-Alonso; G Antiñolo; C Eng
Journal:  J Med Genet       Date:  1999-10       Impact factor: 6.318

3.  RET genotypes comprising specific haplotypes of polymorphic variants predispose to isolated Hirschsprung disease.

Authors:  S Borrego; A Ruiz; M E Saez; O Gimm; X Gao; M López-Alonso; A Hernández; F A Wright; G Antiñolo; C Eng
Journal:  J Med Genet       Date:  2000-08       Impact factor: 6.318

Review 4.  Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects.

Authors:  N J Sarlis
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

5.  KinMutBase, a database of human disease-causing protein kinase mutations.

Authors:  K A Stenberg; P T Riikonen; M Vihinen
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

6.  RET proto-oncogene mutations are restricted to codon 618 in Cypriot families with multiple endocrine neoplasia 2.

Authors:  V Neocleous; N Skordis; G Portides; E Efstathiou; C Costi; N Ioannou; M Pantzaris; V Anastasiadou; C Deltas; L A Phylactou
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

7.  Case report: a p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma.

Authors:  X-P Qi; R-B Ying; J-M Ma; W-T Liu; Z-F Du; J Fei; C-P Yang; Q-Z Song; H-Y Jin; Z-G Chen; J-S Han; J-Q Wang; X-L Chen; Y Zhao; J-J Lu; X-N Zhang
Journal:  Fam Cancer       Date:  2012-03       Impact factor: 2.375

8.  Nine novel germline gene variants in the RET proto-oncogene identified in twelve unrelated cases.

Authors:  Syed A Ahmed; Karen Snow-Bailey; W Edward Highsmith; Weimin Sun; Raymond G Fenwick; Rong Mao
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

9.  RET proto-oncogene genotyping using unlabeled probes, the masking technique, and amplicon high-resolution melting analysis.

Authors:  Rebecca L Margraf; Rong Mao; W Edward Highsmith; Leonard M Holtegaard; Carl T Wittwer
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

Review 10.  Hereditary syndromes predisposing to endocrine tumors and their skin manifestations.

Authors:  Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.